Toll-like Receptor 2 in Autoimmune Inflammation

키워드

참고문헌 (82)

1. Davidson A, "Autoimmune diseases", N Engl J Med, 345, pp.340~350 (2001)
2. Cooper GS, "The epidemiology of autoimmune diseases", Autoimmun Rev, 2, pp.119~125 (2003)
3. Jadidi-Niaragh F, "Th17 cell, the new player of neuroinflammatory process in multiple sclerosis", Scand J Immunol, 74, pp.1~13 (2011)
4. Yasuda K, "The pathogenicity of Th17 cells in autoimmune diseases", Semin Immunopathol, 41, pp.283~297 (2019)
5. Thomas SL, "Burden of mortality associated with autoimmune diseases among females in the United Kingdom", Am J Public Health, 100, pp.2279~2287 (2010)
6. Houge IS, "Mortality is increased in patients with rheumatoid arthritis or diabetes compared to the general population-the Nord-Trøndelag Health Study", Sci Rep, 10, pp.3593~ (2020)
7. Kawai T, "The role of pattern-recognition receptors in innate immunity : update on Toll-like receptors", Nat Immunol, 11, pp.373~384 (2010)
8. Botos I, "The structural biology of Toll-like receptors", Structure, 19, pp.447~459 (2011)
9. Bell JK, "Leucine-rich repeats and pathogen recognition in Toll-like receptors", Trends Immunol, 24, pp.528~533 (2003)
10. Alibashe-Ahmed M, "Toll-like receptor 4 inhibition prevents autoimmune diabetes in NOD mice", Sci Rep, 9, pp.19350~ (2019)
11. Reynolds JM, "Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation", Proc Natl Acad Sci U S A, 109, pp.13064~13069 (2012)
12. Devarapu SK, "Toll-like receptors in lupus nephritis", J Biomed Sci, 25, pp.35~ (2018)
13. Horton CG, "Toll-like receptors in systemic lupus erythematosus : potential targets for therapeutic intervention", Curr Allergy Asthma Rep, 12, pp.1~7 (2012)
14. Marshak-Rothstein A, "Toll-like receptors in systemic autoimmune disease", Nat Rev Immunol, 6, pp.823~835 (2006)
15. Fillatreau S, "Toll-like receptor signalling in B cells during systemic lupus erythematosus", Nat Rev Rheumatol, 17, pp.98~108 (2021)
16. Takeda K, "Toll-like receptors", Annu Rev Immunol, 21, pp.335~376 (2003)
17. Andersson A, "Pivotal advance : HMGB1 expression in active lesions of human and experimental multiple sclerosis", J Leukoc Biol, 84, pp.1248~1255 (2008)
18. Jafarzadeh A, "The Toll-like receptor 2(TLR2)-related immunopathological responses in the multiple sclerosis and experimental autoimmune encephalomyelitis", Iran J Allergy Asthma Immunol, 18, pp.230~250 (2019)
19. Sloane JA, "Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2", Proc Natl Acad Sci U S A, 107, pp.11555~11560 (2010)
20. Shi B, "SNAPIN : an endogenous Toll-like receptor ligand in rheumatoid arthritis", Ann Rheum Dis, 71, pp.1411~1417 (2012)
21. Gray DH, "Danger-free autoimmune disease in Aire-deficient mice", Proc Natl Acad Sci U S A, 104, pp.18193~18198 (2007)
22. Cohen SJ, "IL-10 mediates resistance to adoptive transfer experimental autoimmune encephalomyelitis in MyD88(-", -)mice, 2010, pp.184, 212~221
23. Sadanaga A, "Protection against autoimmune nephritis in MyD88-deficient MRL", lpr mice, 2007, pp.56, 1618~1628
24. Dishon S, "Inhibition of myeloid differentiation factor 88 reduces human and mouse T-cell interleukin-17 and IFNγ production and ameliorates experimental autoimmune encephalomyelitis induced in mice", Front Immunol, 8, pp.615~ (2017)
25. Adachi O, "Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function", Immunity, 9, pp.143~150 (1998)
26. Chung Y, "Critical regulation of early Th17 cell differentiation by interleukin-1 signaling", Immunity, 30, pp.576~587 (2009)
27. Urbonaviciute V, "Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus", Arthritis Rheum, 65, pp.1612~1623 (2013)
28. Lartigue A, "Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus", J Immunol, 183, pp.6207~6216 (2009)
29. Ma K, "Roles of B Cell-Intrinsic TLR Signals in Systemic Lupus Erythematosus", Int J Mol Sci, 16, pp.13084~13105 (2015)
30. Freeley SJ, "Toll-like receptor 2 or toll-like receptor 4 deficiency does not modify lupus in MRLlpr mice", PLoS One, 8, pp.e74112~ (2013)
31. Reynolds JM, "IL-17 family member cytokines : regulation and function in innate immunity", Cytokine Growth Factor Rev, 21, pp.413~423 (2010)
32. Reynolds JM, "Toll-like receptor 2 signaling in CD4(+)T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease", Immunity, 32, pp.692~702 (2010)
33. Devaraj S, "Knockout of toll-like receptor-2attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy", Arterioscler Thromb Vasc Biol, 31, pp.1796~1804 (2011)
34. Frasnelli ME, "TLR2 modulates inflammation in zymosaninduced arthritis in mice", Arthritis Res Ther, 7, pp.R370~R379 (2005)
35. Seibl R, "Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium", Am J Pathol, 162, pp.1221~1227 (2003)
36. Ultaigh SN, "Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures", Arthritis Res Ther, 13, pp.R33~ (2011)
37. Fujiwara M, "Enhanced TLR2 responses in multiple sclerosis", Clin Exp Immunol, 193, pp.313~326 (2018)
38. Dalia Ahmed Labib, "Toll-like receptors 2 and 4 expression on peripheral blood lymphocytes and neutrophils of Egyptian multiple sclerosis patients", International Journal of Neuroscience, pp.1~5 (2020), Informa UK Limited[DOI]
39. Hossain MJ, "The soluble form of Toll-like receptor 2 is elevated in serum of multiple sclerosis patients : a novel potential disease biomarker", Front Immunol, 9, pp.457~ (2018)
40. Lacerte P, "Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists", Arthritis Res Ther, 18, pp.10~10 (2016)
41. Flo TH, "Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide", J Immunol, 164, pp.2064~2069 (2000)
42. Huang Q, "Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis", Arthritis Rheum, 56, pp.2192~2201 (2007)
43. Quero L, "TLR2 stimulation impairs anti-inflammatory activity of M2-like macrophages, generating a chimeric M1", M2 phenotype, 2017, pp.19, 245~245
44. Korganow AS, "From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins", Immunity, 10, pp.451~461 (1999)
45. Huang QQ, "TLR2 deletion promotes arthritis through reduction of IL-10", J Leukoc Biol, 93, pp.751~759 (2013)
46. Foster SL, "Gene-specific control of inflammation by TLR-induced chromatin modifications", Nature, 447, pp.972~978 (2007)
47. Huang QQ, "The role of Toll-like receptors in rheumatoid arthritis", Curr Rheumatol Rep, 11, pp.357~364 (2009)
48. Wasko NJ, "Systemic TLR2 tolerance enhances central nervous system remyelination", J Neuroinflammation, 16, pp.158~ (2019)
49. Anstadt EJ, "TLR tolerance as a treatment for central nervous system autoimmunity", J Immunol, 197, pp.2110~2118 (2016)
50. Kim DH, "Inhibition of autoimmune diabetes by TLR2tolerance", J Immunol, 187, pp.5211~5220 (2011)
51. Candia L, "Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity?", J Rheumatol, 34, pp.374~379 (2007)
52. Wang X, "Expression of Toll-like receptor 2 by dendritic cells is essential for the DnaJ-ΔA146Ply-mediated Th1 immune response against Streptococcus pneumoniae", Infect Immun, 86, pp.e00651~e00617 (2018)
53. Roelofs MF, "Expression of Toll-like receptor (TLR) 2, TLR3, TLR4 and TLR7 is increased in rheumatoid arthritis synovium and regulates cytokine production by dendritic cells upon stimulation of TLR specific pathways", Arthritis Res Ther, 7(Suppl 1), pp.P70~ (2005)
54. Lee DS, "B cell depletion therapies in autoimmune disease : advances and mechanistic insights", Nat Rev Drug Discov, 20, pp.179~199 (2021)
55. Agrawal S, "TLR1", 2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors, 2011, pp.31, 89~98
56. Green NM, "Toll-like receptor driven B cell activation in the induction of systemic autoimmunity", Semin Immunol, 23, pp.106~112 (2011)
57. Correale J, "Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms", J Immunol, 183, pp.5999~6012 (2009)
58. Lampropoulou V, "TLR-activated B cells suppress T cell-mediated autoimmunity", J Immunol, 180, pp.4763~4773 (2008)
59. Kabelitz D, "Expression and function of Toll-like receptors in T lymphocytes", Curr Opin Immunol, 19, pp.39~45 (2007)
60. Ye J, "TLR7 signaling regulates Th17 cells and autoimmunity : novel potential for autoimmune therapy", J Immunol, 199, pp.941~954 (2017)
61. Ferreira TB, "Different interleukin-17-secreting Toll-like receptor+T-cell subsets are associated with disease activity in multiple sclerosis", Immunology, 154, pp.239~252 (2018)
62. Imanishi T, "mTORC1 signaling controls TLR2-mediated T-cell activation by inducing TIRAP expression", Cell Reports, 32, pp.107911~ (2020)
63. Komai-Koma M, "TLR2 is expressed on activated T cells as a costimulatory receptor", Proc Natl Acad Sci U S A, 101, pp.3029~3034 (2004)
64. Jun JC, "T cell-intrinsic TLR2 stimulation promotes IL-10 expression and suppressive activity by CD45RbHi T cells", PLoS One, 12, pp.e0180688~ (2017)
65. Cottalorda A, "TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation", Eur J Immunol, 36, pp.1684~1693 (2006)
66. Liew FY, "A toll for T cell costimulation", Ann Rheum Dis, 63(Suppl 2), pp.ii76~ii78 (2004)
67. Nyirenda MH, "TLR2 stimulation regulates the balance between regulatory T cell and Th17 function : a novel mechanism of reduced regulatory T cell function in multiple sclerosis", J Immunol, 194, pp.5761~5774 (2015)
68. Nyirenda MH, "TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function", J Immunol, 187, pp.2278~2290 (2011)
69. Kathryne Marks, "Toll-Like Receptor 2 Induces Pathogenicity in Th17 Cells and Reveals a Role For Interactor Protein for Cytohesin Exchange Factors 1 (IPCEF) In Regulating Th17 Cell Migration", Cell Rep (2021), Elsevier BV[DOI]
70. Nyirenda MH, "TLR2 stimulation regulates the balance between regulatory T cell and Th17 function : a novel mechanism of reduced regulatory T cell function in multiple sclerosis", J Immunol, 194, pp.5761~5774 (2015)
71. Dejaco C, "Imbalance of regulatory T cells in human autoimmune diseases", Immunology, 117, pp.289~300 (2006)
72. Havrdová E, "Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS : results from a randomized, proof-of-concept study", J Neurol, 263, pp.1287~1295 (2016)
73. Taams LS, "Interleukin-17 in rheumatoid arthritis : trials and tribulations", J Exp Med, 217, pp.e20192048~ (2020)
74. Ye J, "TLR7 signaling regulates Th17 cells and autoimmunity : novel potential for autoimmune therapy", J Immunol, 199, pp.941~954 (2017)
75. McAleer JP, "Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization", J Leukoc Biol, 88, pp.21~31 (2010)
76. Dias AS, "TLR-2 and TLR-4 agonists favor expansion of CD4+T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders", Mult Scler Relat Disord, 34, pp.66~76 (2019)
77. Zhao RR, "Toll-like receptor 2 promotes T helper 17 cells response in hepatitis B virus infection", Int J Clin Exp Med, 8, pp.7315~7323 (2015)
78. Young KE, "Fatty acid synthase regulates the pathogenicity of Th17 cells", J Leukoc Biol, 102, pp.1229~1235 (2017)
79. Elshabrawy HA, "TLRs, future potential therapeutic targets for RA", Autoimmun Rev, 16, pp.103~113 (2017)
80. Mullen LM, "Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease", Arthritis Res Ther, 17, pp.122~ (2015)
81. Mistry P, "Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain", Proc Natl Acad Sci U S A, 112, pp.5455~5460 (2015)
82. Anwar MA, "Recent clinical trends in Toll-like receptor targeting therapeutics", Med Res Rev, 39, pp.1053~1090 (2019)

관련 논문AI추천